Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyFri, 16 Aug 2024 08:47:11 +0200Tue, 11 Jun 2024 09:36:00 +0200Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 4, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/libmyrisHuman medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 4, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/libmyrisTue, 11 Jun 2024 09:36:00 +0200Human medicineLibmyris : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5947_en_3.pdfLibmyris : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5947_en_3.pdfTue, 11 Jun 2024 09:30:00 +0200Human medicine